[IEEE-bhpjobs] Duke Events of interest

[Walter Heger]

 Genomes @ 4
Thursday, May 19th 2005
On the Road to Personalized Medicine:
Translating Biomarkers into Clinical Medicine
Geoffrey Ginsburg, MD, PhD
Director, IGSP Center for Genomic Medicine
*Please note the location for next week's presentation is 103 Bryan Research
Auditorium.  The Social hour will be held in the IGSP lobby as usual*
Genomes @ 4  is a biweekly interdisciplinary series sponsored by the IGSP
meant to engage diverse perspectives on the genome sciences and their broad
impact on our lives. Each presentation and discussion will run from 4-5pm
followed by an IGSP Social Hour in the 2nd floor lobby.  Please post and
share the attached announcement.




CED Innovator's Workshop:


"The Development of University Technology - Discovery to Commercialization"

Thursday, June 9th, from 5:15-8pm
Fitzpatrick-CIEMAS


Wondering if and when you should commercialize your technology?  Before you
go to a Venture Capitalist, come to our seminar.  Here's your chance to hear
the stories of two recent Duke spin-outs and learn from two of the area's
best venture capitalists about when to commercialize technologies.


Hosted by
The Office of Science and Technology, Duke University
The Pratt School's Master of Engineering Management Program
Health Sector Management Program, Fuqua School of Business
The Council for Entrepreneurial Development [CED]


Details
Where: Schiciano Auditorium, Room 1466, Fitzpatrick Center for
Interdisciplinary Engineering, Medicine and Applied Sciences-FCIEMAS
Cost:    $29. To register, visit www.cednc.org and click "Register for an
Event" then click "Innovator's Workshop".   Or contact Howie Rhee at
hrhee at cednc.org or 919-549-7500 x103.


Agenda
5:15 pm to 5:30 pm - Welcome
Robert Taber, Ph.D., Vice Chancellor for Science and Technology Development
5:30 pm to 6:30 pm - When University Discoveries Should be Commercialized
·         The Affinergy Story
Dan Kenan, M.D., Ph.D. '95, Assistant Professor, Department of Pathology,
Co-founder of Affinergy
and Jonathan Gindes, MBA '03, Co-founder of Affinergy
·         The Centice Story
David Brady, Ph.D., Addy Family Professor of Electrical and Computer
Engineering, Co-founder of Centice
6:30 to 7:00pm - Dinner
7:00 to 8:00pm - Panel: What are Venture Capitalists Looking For?
·         Garheng Kong, Ph.D. '99, M.D. '01, MBA  '03, Partner, Intersouth
Partners
·         Scott Albert, BSE '77, Managing General Partner, Aurora Funds
Moderated by Jeff Glass, Professor, Electrical & Computer Engineering and
Hogg Family Director, Master of Engineering Management Program
8:00 to 9:00pm - Optional Session: Meet with an Expert
Meet with an expert on commercialization and receive advice on if and how to
prepare your own technology for commercialization



About Affinergy
Affinergy's platform technology is embodied in a patent application filed by
Duke University in 2001 and licensed to Affinergy in 2004. Affinergy's
intellectual property portfolio includes patent filings for methods,
compositions, and processes with specific embodiments, as well as related
"know-how" and existing libraries of binders.
In 2004, Affinergy recruited its leadership team and oversubscribed its
initial funding to accelerate development and initiate pre-clinical studies.
Affinergy's scientific co-founders, Dan Kenan, MD., Ph.D. and Mark
Grinstaff, Ph.D. remain very active in building the "Interfacial
Biomaterials" (IFBM) technology for Affinergy. Affinergy was selected to
join the Becton Dickinson Incubator program in Research Triangle Park, North
Carolina.



About Centice
Centice manufactures computational optical spectroscopy and imaging engines
for applications in medicine, chemical process control and national
security. Centice computational sensors combine intelligent sampling
algorithms with proprietary algorithms. This application-specific,
algorithm-based design gives Centice computational sensors a 10-1000x boost
in performance as measured by parameters such as throughput, sensitivity,
specificity, selectivity, and speed--implemented in compact, low cost
programmable devices.
·         Centice originated in the Duke Venture Clinic and, operating under
the name "Optopo", won the Duke Start-Up Challenge in 2004
·         Centice closed series A venture funding in 2004 through The Aurora
Funds and Novak Biddle Venture Partners
·         Centice's computational sensor technology was developed by the
Duke Integrated Sensing and Processing (DISP) group under support from NIH,
DARPA and ARO and is licensed through the Duke Office of Science and
Technology.



About Intersouth Partners
Intersouth Partners is one of the most active and experienced early-stage
venture funds in the Southeast, having invested in more than 75 private
companies over the last nineteen years. Founded in 1985, Intersouth manages
more than $500 million in six venture capital limited partnerships, making
it the largest venture capital fund in North Carolina and one of the largest
in the Southeast.
Based in Durham, NC, Intersouth Partners seeks a broad range of investment
opportunities in the information technology and life sciences sectors. Our
experienced team has full-cycle experience in the complex matters associated
with investing in fledgling companies, including management team
development, technology assessment and transfer, corporate partnering and
successful exits.



About Aurora Funds
The Aurora Funds is a venture capital firm that provides capital,
connections and strategic guidance to entrepreneurs with early-stage life
sciences and information technology companies.  Founded in 1994, Aurora
manages over $155 million in four venture funds.  The firm's six investment
professionals have over 100 years of combined venture capital investing and
operational experience.  The Aurora team has managed investments in over 50
companies, resulting in five IPOs and eight M&A transactions to date.
Aurora typically is a lead or co-lead investor in seed and early-stage
financing opportunities located primarily in the Southeastern and
mid-Atlantic United States.  The firm's initial investment size ranges from
$50,000 in a seed investment to as much as $2.5 million in a first round
financing. Aurora has the capacity to invest a total of between $4 million
and $8 million across multiple rounds of financing as the company matures.